Exhibit 1.1
PHIBRO ANIMAL HEALTH CORPORATION
(a Delaware corporation)
[l]
Shares of Common Stock
UNDERWRITING AGREEMENT
Dated: [l], 2014
PHIBRO ANIMAL HEALTH CORPORATION
(a Delaware corporation)
[l]
Shares of Common Stock
UNDERWRITING AGREEMENT
[l],
2014
Xxxxxxx Lynch, Pierce, Xxxxxx &
Xxxxx
Incorporated.
Xxxxxx Xxxxxxx & Co. LLC
| c/o | Merrill Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated |
Xxx Xxxxxx Xxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Phibro Animal Health Corporation,
a Delaware corporation (the “Company”) and Mayflower Limited Partnership, a Jersey limited partnership, (the “Selling
Stockholder”) confirm their respective agreements with Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated (“Xxxxxxx
Xxxxx”) and Xxxxxx Xxxxxxx & Co. LLC (“Xxxxxx Xxxxxxx”) and each of the other Underwriters named in Schedule
A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter
provided in Section 10 hereof), for whom Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx are acting as representatives (in such capacity,
the “Representatives”), with respect to (i) the sale by the Company and the Selling Stockholder, acting severally and
not jointly, and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common
Stock, par value $[•] per share, of the Company (“Common Stock”) set forth in Schedules A and B hereto and
(ii) the grant by the Selling Stockholder to the Underwriters, acting severally and not jointly, of the option described in Section 2(b)
hereof to purchase all or any part of [l] additional shares of Common Stock. The aforesaid
[l] shares of Common Stock (the “Initial Securities”) to be purchased by
the Underwriters and all or any part of the [l] shares of Common Stock subject to the
option described in Section 2(b) hereof (the “Option Securities”) are herein called, collectively, the “Securities.”
The Company and the Selling
Stockholder understand that the Underwriters propose to make a public offering of the Securities as soon as the Representatives
deem advisable after this Agreement has been executed and delivered.
The Company has filed with
the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1 (No. 333-l),
including the related preliminary prospectus or prospectuses, covering the registration of the sale of the Securities under the
Securities Act of 1933, as amended (the “1933 Act”). Promptly after execution and delivery of this Agreement, the Company
will prepare and file a prospectus in accordance with the provisions of Rule 430A (“Rule 430A”) of the rules
and regulations of the Commission
under the 1933 Act (the “1933 Act Regulations”) and Rule 424(b) (“Rule 424(b)”) of the 1933 Act Regulations.
The information included in such prospectus that was omitted from such registration statement at the time it became effective but
that is deemed to be part of such registration statement at the time it became effective pursuant to Rule 430A(b) is herein called
the “Rule 430A Information.” Such registration statement, including the amendments thereto, the exhibits thereto and
any schedules thereto, at the time it became effective, and including the Rule 430A Information, is herein called the “Registration
Statement.” Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the “Rule
462(b) Registration Statement” and, after such filing, the term “Registration Statement” shall include the Rule
462(b) Registration Statement. Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus
that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement,
is herein called a “preliminary prospectus.” The final prospectus, in the form first furnished to the Underwriters
for use in connection with the offering of the Securities, is herein called the “Prospectus.” For purposes of this
Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement
to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval system or any successor system (“XXXXX”).
As used in this Agreement:
“Applicable
Time” means [l:00 P./A.M.], New York City time, on [l],
2014 or such other time as agreed by the Company and the Representatives.
“General
Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the
most recent preliminary prospectus that is distributed to investors prior to the Applicable Time and the information included on
Schedule C-1 hereto, all considered together.
“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act Regulations
(“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the
1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to be filed with the Commission
by the Company, (ii) a “road show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether
or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the
form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g).
“Issuer
General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433 (the “Bona
Fide Electronic Road Show”)), as evidenced by its being specified in Schedule C-2 hereto.
“Issuer
Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.
“Testing-the-Waters
Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of
the 1933 Act.
“Written
Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the 1933 Act.
SECTION 1. Representations
and Warranties.
(a) Representations
and Warranties by the Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable
Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:
(i) Registration
Statement and Prospectuses. Each of the Registration Statement and any post-effective amendment thereto has become effective
under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto
has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has
been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge,
contemplated. The Company has complied with each request (if any) from the Commission for additional information.
Each of the Registration
Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the
requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement
thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act
and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with this offering
and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant
to XXXXX, except to the extent permitted by Regulation S-T.
(ii) Accurate
Disclosure. Neither the Registration Statement nor any post-effective amendment thereto, at its effective time, at the Closing
Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or
will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As
of the Applicable Time, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus,
when considered together with the General Disclosure Package and (C) and individual Written Testing-the-Waters Communication, when
considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact
or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including
any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing
Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or
will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading.
The representations
and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any post-effective
amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance
upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly
for use therein. For purposes of this
Agreement, the
only information so furnished shall be [●] in each case contained in the Prospectus (collectively, the “Underwriter
Information”).
(iii) Issuer
Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the
Registration Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been
superseded or modified. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) such
that no filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities.
(iv) Testing-the-Waters
Materials. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications
with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under
the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B) has not authorized
anyone other than the Representatives to engage in Testing-the-Waters Communications. The Company reconfirms that the Representatives
have been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any
Written Testing-the-Waters Communications other than those listed on Schedule E hereto.
(v) Company
Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2)
of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,”
as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary
that the Company be considered an ineligible issuer.
(vi) Emerging
Growth Company Status. From the time of the initial confidential submission of the Registration Statement to the Commission
(or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in
any Testing-the-Waters Communication) through the date hereof, the Company has been and is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
(vii) Independent
Accountants. The accountants who certified the financial statements and supporting schedules included in the Registration Statement,
the General Disclosure Package and the Prospectus are independent public accountants with respect to the Company as required by
the 1933 Act, the 1933 Act Regulations and the Public Accounting Oversight Board.
(viii) Financial
Statements; Non-GAAP Financial Measures. The financial statements included in the Registration Statement, the General Disclosure
Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial
position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders’
equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have
been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis
throughout the periods involved except, in the case of unaudited financial statements, subject to normal year end audit adjustments
and the exclusion of certain footnotes as permitted by the applicable rules of the Commission. The supporting schedules, if any,
present fairly, in all material respects, in accordance with GAAP the information required to be stated therein. The
selected financial
data and the summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus
present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that
of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements
or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure
Package or the Prospectus under the 1933 Act or the 1933 Act Regulations.
(ix) No
Material Adverse Change in Business. Except as otherwise stated therein, since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse
change in the condition, financial or otherwise, or in the earnings, business operations or business prospects of the Company and
its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse
Effect”), (B) there have been no transactions entered into by the Company or any of its subsidiaries, other than those
in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise,
and (C) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its
capital stock.
(x) Good
Standing of the Company. The Company has been duly organized and is validly existing as a corporation in good standing under
the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and
perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and
is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not reasonably be
expected to result in a Material Adverse Effect.
(xi) Good
Standing of Subsidiaries. Each “significant subsidiary” of the Company (as such term is defined in Rule 1-02 of
Regulation S-X) (each, a “Subsidiary” and, collectively, the “Subsidiaries”) has been duly organized and
is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or
similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing
in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the
conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected to result
in a Material Adverse Effect. Except as otherwise described in the Registration Statement, the General Disclosure Package and the
Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is
fully paid and non-assessable and is owned by the Company, directly or through subsidiaries, free and clear of any security interest,
mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued
in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only subsidiaries of the Company
are (A) the subsidiaries listed on Exhibit 21 to the Registration Statement and (B) certain other subsidiaries which, considered
in the aggregate as a single subsidiary, do not constitute a “significant subsidiary” as defined in Rule 1-02 of Regulation
S-X.
(xii) Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the
General Disclosure Package and
the Prospectus
in the column entitled “Actual” under the caption “Capitalization” (except for subsequent issuances, if
any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the Registration
Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities or options referred
to in the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of
the Company, including the Securities to be purchased by the Underwriters from the Selling Stockholder, have been duly authorized
and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company, including
the Securities to be purchased by the Underwriters from the Selling Stockholder, were issued in violation of the preemptive or
other similar rights of any securityholder of the Company.
(xiii) Authorization
of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(xiv) Authorization
and Description of Securities. The Securities to be purchased by the Underwriters from the Company have been duly authorized
for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to
this Agreement against payment of the consideration set forth herein, will be validly issued and fully paid and non-assessable;
and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company.
The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement,
the General Disclosure Package and the Prospectus and such description conforms in all material respects to the rights set forth
in the instruments defining the same. No holder of Securities will be subject to personal liability by reason of being such a holder.
(xv) Registration
Rights. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement.
(xvi) Absence
of Violations, Defaults and Conflicts. Neither the Company nor any of its subsidiaries is (A) in violation of its charter,
by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant
or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which
any of the properties or assets of the Company or any subsidiary is subject (collectively, “Agreements and Instruments”),
except for such defaults that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect,
or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental
body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of
its subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except
for such violations that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the
Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and
the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”) and
compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not
and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of,
or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien,
charge or encumbrance upon any properties or assets
of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults
or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, reasonably be expected to
result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws
or similar organizational document of the Company or any of its subsidiaries or, except as would not reasonably be expected
to result in a Material Adverse Effect, any law, statute, rule, regulation, judgment, order, writ or decree of any
Governmental Entity. As used herein, a “Repayment Event” means any event or condition which gives the holder of
any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to
require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its
subsidiaries.
(xvii) Absence
of Labor Dispute. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge
of the Company, is imminent, and which, in either case, would reasonably be expected to result in a Material Adverse Effect.
(xviii) Absence
of Proceedings. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, there
is no action, suit, proceeding, inquiry or, to the knowledge of the Company, investigation before or brought by any Governmental
Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries,
which would reasonably be expected to result in a Material Adverse Effect, or which might materially and adversely affect their
respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the
Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or
any such subsidiary is a party or of which any of their respective properties or assets is the subject which are not described
in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental
to the business, would not reasonably be expected to result in a Material Adverse Effect.
(xix) Accuracy
of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement, the General
Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described
in all material respects and filed as required.
(xx) Absence
of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification or
decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in
connection with the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated
by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations,
the rules of the NASDAQ, state securities laws or the rules of FINRA. ¶
(xxi) Possession
of Licenses and Permits. The Company and its subsidiaries possess such permits, licenses, approvals, consents and other authorizations
(collectively, “Governmental Licenses”) issued by the appropriate Governmental Entities necessary to conduct the business
now operated by them, except where the failure so to possess would not, singly or in the aggregate, reasonably be expected to result
in a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental
Licenses, except where the failure so to comply would not, singly or in the aggregate, reasonably be expected to result in a Material
Adverse Effect. All of the Governmental Licenses are valid and
in full force and
effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force
and effect would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental
Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected
to result in a Material Adverse Effect.
(xxii) Title
to Property. The Company and its subsidiaries have good and marketable title to all real property owned by them and good title
to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims,
restrictions or encumbrances of any kind except such as are described in the Registration Statement, the General Disclosure Package
and the Prospectus and all of the leases and subleases material to the business of the Company and its subsidiaries, considered
as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration Statement,
the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary
has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary
under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary
to the continued possession of the leased or subleased premises under any such lease or sublease; except, in each case, as would
not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
(xxiii) Possession
of Intellectual Property. The Company and its subsidiaries own or possess, or can acquire on commercially reasonable terms,
adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or
unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual
property (collectively, “Intellectual Property”) necessary to carry on the business now operated by them, and neither
the Company nor any of its subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted
rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual
Property invalid or inadequate to protect the interest of the Company or any of its subsidiaries therein, and which infringement
or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate,
would reasonably be expected to result in a Material Adverse Effect.
(xxiv) Environmental
Laws. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly
or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (A) neither the Company nor any of its subsidiaries
is in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule
of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent,
decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient
air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release or threatened release of hazardous chemicals, pollutants, contaminants, hazardous wastes, toxic substances,
hazardous substances, petroleum or petroleum products, asbestos-containing materials or toxic mold (collectively, “Hazardous
Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and its subsidiaries have all permits, authorizations
and approvals required under any applicable Environmental Laws for the operation of their business or the occupancy of their real
property and are each in compliance with their
requirements and
(C) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits,
demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings or, to the Company’s
knowledge, investigations relating to any Environmental Law against the Company or any of its subsidiaries and (D) there are no
events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action,
suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating
to Hazardous Materials or any Environmental Laws.
(xxv) Hazardous
Materials. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, there has
been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by,
relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any
other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably
be expected to be liable) at, on, under, to or from any property or facility now or, to the knowledge of the Company, previously
owned, operated or leased by the Company or any of its subsidiaries, or, to the knowledge of the Company, at, on, under, to or
from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could
reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. “Release” means any
spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing,
depositing, dispersing, or migrating in, into or through the environment, or in, into, from or through any building or structure.
(xxvi) Compliance
with ERISA. Except, in each case, for any such matter as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect, (i) each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group”
(defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal
Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained
in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not
limited to, ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the
Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption;
(iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, the minimum funding
standard of Section 412 of the Code or Section 302 of ERISA, as applicable, has been satisfied (without taking into account any
waiver thereof or extension of any amortization period); (iv) no “reportable event” (within the meaning of Section
4043(c) of ERISA) has occurred or is reasonably expected to occur; (v) neither the Company nor any member of the Controlled Group
has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums
to the PBGC, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan,” within
the meaning of Section 4001(a)(3) of ERISA); and (vi) there is no pending audit or investigation by the Internal Revenue Service,
the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory
agency with respect to any Plan.
(xxvii) Accounting
Controls. The Company has taken all necessary actions to ensure that, in the time period required the Company will comply with
Rule 13-a15 and 15d-15 under the rules and regulations of the Commission (the “1934 Act Regulations”) under the Securities
Exchange Act of 1934, as amended (the “1934 Act”) and the Company maintains a system of internal accounting controls
sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or
specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s
general or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as described in the Registration Statement, the
General Disclosure Package and the Prospectus, since the end of the Company’s most recent audited fiscal year, there has
been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and
(2) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely
to materially affect, the Company’s internal control over financial reporting.
(xxviii) Payment
of Taxes. All United States federal income tax returns of the Company and its subsidiaries required by law to be filed have
been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments
against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The United States
federal income tax returns of the Company through the fiscal year ended June 30, 2006 have been settled and no assessment in connection
therewith has been made against the Company. The Company and its subsidiaries have filed all other tax returns that are required
to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such
returns would not reasonably be expected to result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns
or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested
in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the
books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to
meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of
any inadequacy that would not reasonably be expected to result in a Material Adverse Effect.
(xxix) Insurance. The Company and its subsidiaries carry or are entitled to the benefits of insurance, with reputable insurers, in such amounts and
covering such risks as the Company’s management reasonably believes is adequate to protect the Company and its subsidiaries
and their businesses, taken as a whole, and all such insurance is in full force and effect. The Company has no reason to believe
that it or any of its subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies
expire or (B) to obtain reasonably comparable coverage from similar institutions as may be necessary or appropriate to conduct
its business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Effect. Neither
of the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.
(xxx) Investment
Company Act. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application
of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will
not be required, to register as an “investment company” under the Investment Company Act of 1940, as amended (the “1940
Act”).
(xxxi) Absence
of Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take,
directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in
a violation of Regulation M under the 1934 Act.
(xxxii) Foreign
Corrupt Practices Act. None of the Company, any of its subsidiaries and affiliates or, to the knowledge of the Company, any
director, officer, agent, employee, or other person acting on behalf of the Company or any of its subsidiaries is aware of or has
taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act
of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use
of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay
or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything
of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official
thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the
Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and
procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
(xxxiii)
Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering
Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(xxxiv) OFAC. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate,
or representative of the Company or any of its subsidiaries is an individual or entity (“Person”) currently the subject
or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department
of the Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”),
the European Union, Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”),
nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will
not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such
proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or
in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result
in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor
or otherwise) of Sanctions.
(xxxv)
Lending Relationship. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
the Company (i) does not have any material lending or other relationship with any bank or lending affiliate of any Underwriter
and (ii) does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to
any affiliate of any Underwriter.
(xxxvi) Statistical
and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the General Disclosure
Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable
and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.
(b) Representations
and Warranties by the Selling Stockholder. The Selling Stockholder represents and warrants to each Underwriter as of the date
hereof, as of the Applicable Time, as of the Closing Time and, if the Selling Stockholder is selling Option Securities on a Date
of Delivery, as of each such Date of Delivery, and agrees with each Underwriter, as follows:
(i) Accurate
Disclosure. Neither the General Disclosure Package nor the Prospectus or any amendments or supplements thereto includes any
untrue statement of a material fact or omits to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided that such representations and warranties set forth
in this subsection (b)(i) apply only to statements or omissions made in reliance upon and in conformity with information relating
to such Selling Stockholder furnished in writing by or on behalf of such Selling Stockholder expressly for use in the Registration
Statement, the General Disclosure Package, the Prospectus or any other Issuer Free Writing Prospectus or any amendment or supplement
thereto (the “Selling Stockholder Information”); the Selling Stockholder is not prompted to sell the Securities to
be sold by the Selling Stockholder hereunder by any information concerning the Company or any subsidiary of the Company which is
not set forth in the General Disclosure Package or the Prospectus.
(ii) Authorization
of this Agreement. This Agreement has been duly authorized, executed and delivered by or on behalf of the Selling Stockholder.
(iii) Non-contravention. The execution and delivery of this Agreement and the sale and delivery of the Securities to be sold by the Selling Stockholder
and the consummation of the transactions contemplated herein and compliance by the Selling Stockholder with its obligations hereunder
do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach
of, or default under, or result in the creation or imposition of any tax, lien, charge or encumbrance upon the Securities to be
sold by the Selling Stockholder or any property or assets of the Selling Stockholder pursuant to any contract, indenture, mortgage,
deed of trust, loan or credit agreement, note, license, lease or other agreement or instrument to which the Selling Stockholder
is a party or by which the Selling Stockholder may be bound, or to which any of the property or assets of the Selling Stockholder
is subject, nor will such action result in any violation of the provisions of the charter or by-laws or other organizational instrument
of the Selling Stockholder, if applicable, or any applicable treaty, law, statute, rule, regulation, judgment, order, writ or decree
of any government, government instrumentality or court, domestic or foreign, having jurisdiction over the Selling Stockholder or
any of its properties.
(v) Valid
Title. The Selling Stockholder has, and at the Closing Time and, if the Selling Stockholder is selling Option Securities on
a Date of Delivery, as of each such Date of Delivery, will have, valid title to the Securities to be sold by the Selling Stockholder
at such time free and clear of all security interests, claims, liens, equities or other encumbrances and the legal right and power,
and all authorization and approval required by law, to enter into this Agreement and to sell, transfer and deliver the Securities
to be sold by the Selling Stockholder or a valid security entitlement in respect of such Securities.
(vi) Delivery
of Securities. Upon payment of the purchase price for the Securities to be sold by the Selling Stockholder pursuant to this
Agreement, delivery of such Securities, as directed by the Underwriters, to Cede & Co. (“Cede”) or such other nominee
as may be designated by The Depository Trust Company (“DTC”) (unless delivery of such Securities is unnecessary because
such Securities are already in possession of Cede or such nominee), registration of such Securities in the name of Cede or such
other nominee (unless registration of such Securities is unnecessary because such Securities are already registered in the name
of Cede or such nominee), and the crediting of such Securities on the books of DTC to securities accounts (within the meaning of
Section 8-501(a) of the UCC) of the Underwriters (assuming that neither DTC nor any such Underwriter has notice of any “adverse
claim,” within the meaning of Section 8-105 of the Uniform Commercial Code then in effect in the State of New York (“UCC”),
to such Securities), (A) under Section 8-501 of the UCC, the Underwriters will acquire a valid “security entitlement”
in respect of such Securities and (B) no action (whether framed in conversion, replevin, constructive trust, equitable lien, or
other theory) based on any “adverse claim,” within the meaning of Section 8-102 of the UCC, to such Securities may
be asserted against the Underwriters with respect to such security entitlement; for purposes of this representation, such Selling
Stockholder may assume that when such payment, delivery (if necessary) and crediting occur, (I) such Securities will have been
registered in the name of Cede or another nominee designated by DTC, in each case on the Company’s share registry in accordance
with its certificate of incorporation, bylaws and applicable law, (II) DTC will be registered as a “clearing corporation,”
within the meaning of Section 8-102 of the UCC, (III) appropriate entries to the accounts of the several Underwriters on the records
of DTC will have been made pursuant to the UCC, (IV) to the extent DTC, or any other securities intermediary which acts as “clearing
corporation” with respect to the Securities, maintains any “financial asset” (as defined in Section 8-102(a)(9)
of the UCC in a clearing corporation pursuant to Section 8-111 of the UCC, the rules of such clearing corporation may affect the
rights of DTC or such securities intermediaries and the ownership interest of the Underwriters, (V) claims of creditors of DTC
or any other securities intermediary or clearing corporation may be given priority to the extent set forth in Section 8-511(b)
and 8-511(c) of the UCC and (VI) if at any time DTC or other securities intermediary does not have sufficient Securities to satisfy
claims of all of its entitlement holders with respect thereto then all holders will share pro rata in the Securities then held
by DTC or such securities intermediary.
(vii) Absence
of Manipulation. The Selling Stockholder has not taken, and will not take, directly or indirectly, any action which is designed
to or which constituted or would be expected to cause or result in stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.
(viii) Absence
of Further Requirements. No filing with, or consent, approval, authorization, order, registration, qualification or decree
of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency, domestic
or foreign, is necessary or required for the performance by the Selling Stockholder of its obligations hereunder or in connection
with the sale and delivery of the Securities hereunder or the consummation of the transactions contemplated by this Agreement,
except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the Securities Exchange
Act of 1934, as amended, the rules of the NASDAQ, state securities laws or the rules of FINRA.
(ix) No
Registration or Other Similar Rights. The Selling Stockholder does not have any registration or other similar rights to have
any equity or debt securities registered for sale by
the Company under
the Registration Statement or included in the offering contemplated by this Agreement.
(x) No
Free Writing Prospectuses. The Selling Stockholder has not prepared or had prepared on its behalf or used or referred to, any
“free writing prospectus” (as defined in Rule 405), and has not distributed any written materials in connection with
the offer or sale of the Securities.
(c) Officer’s
Certificates. Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the Representatives
or to counsel for the Underwriters shall be deemed a representation and warranty by the Company (and not by such officer in his
personal capacity) to each Underwriter as to the matters covered thereby; and any certificate signed by or on behalf of the Selling
Stockholder as such and delivered to the Representatives or to counsel for the Underwriters pursuant to the terms of this Agreement
shall be deemed a representation and warranty by such Selling Stockholder (and not by such officer in his personal capacity) to
the Underwriters as to the matters covered thereby.
SECTION 2. Sale
and Delivery to Underwriters; Closing.
(a) Initial
Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein
set forth, the Company and the Selling Stockholder, severally and not jointly, agree to sell to each Underwriter, severally and
not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company and the Selling Stockholder,
at the price per share set forth in Schedule A, that proportion of the number of Initial Securities set forth in Schedule B opposite
the name of the Company or the Selling Stockholder, as the case may be, which the number of Initial Securities set forth in Schedule
A opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated
to purchase pursuant to the provisions of Section 10 hereof, bears to the total number of Initial Securities, subject, in each
case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales
or purchases of fractional shares.
(b) Option
Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Selling Stockholder hereby grants an option to the Underwriters, severally and not jointly, to purchase up
to an additional [l] shares of Common Stock, as set forth in Schedule B, at the price
per share set forth in Schedule A, less an amount per share equal to any dividends or distributions declared by the Company and
payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30 days
after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representatives
to the Selling Stockholder setting forth the number of Option Securities as to which the several Underwriters are then exercising
the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date
of Delivery”) shall be determined by the Representatives, but shall not be later than seven full business days after the
exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the
Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number
of Option Securities then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such
Underwriter bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives
in their sole discretion shall make to eliminate any sales or purchases of fractional shares.
(c) Payment.
Payment of the purchase price for, and delivery of certificates for, the Initial Securities shall be made at the offices of Xxxxxxxx
& Xxxxxxxx LLP, 000 Xxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 or at such other place as shall be agreed upon by the Representatives
and the Company and
the Selling Stockholder,
at 9:00 A.M. (New York City time) on the fourth (fifth, if the pricing occurs after 4:30 P.M. (New York City time) on any
given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such
other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company and
the Selling Stockholder (such time and date of payment and delivery being herein called “Closing Time”).
In addition, in the event
that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of
certificates for, such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed
upon by the Representatives and the Company and the Selling Stockholder, on each Date of Delivery as specified in the notice from
the Representatives to the Company and the Selling Stockholder.
Payment shall be made to
the Company and the Selling Stockholder by wire transfer of immediately available funds to bank accounts designated by the Company
and the Selling Stockholder, as the case may be, against delivery to the Representatives for the respective accounts of the Underwriters
of certificates for the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representatives,
for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the
Option Securities, if any, which it has agreed to purchase. Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx, individually and not as representatives
of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option
Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date
of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.
SECTION 3. Covenants
of the Company and the Selling Stockholder. Each of the Company and the Selling Stockholder, as applicable, covenants with
each Underwriter as follows:
(a) Compliance
with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the requirements
of Rule 430A, and will notify the Representatives promptly, and confirm the notice in writing, (i) when any post-effective amendment
to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of
the receipt of any comments from the Commission with respect to the Registration Statement or the Prospectus, (iii) of any
request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for
additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto or of any order preventing or suspending the use of any preliminary prospectus
or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e)
of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section
8A of the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b),
in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps
as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received
for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every
reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain
the lifting thereof at the earliest possible moment.
(b) Continued
Compliance with Securities Laws. The Company will comply with the 1933 Act and the 1933 Act Regulations so as to permit the
completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General
Disclosure Package and
the Prospectus. If at any
time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations
(“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event
shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for
the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package
or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered
to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus,
as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly
(A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such
statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such
requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any
such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall
not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The
Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably
request. The Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to
the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such
proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the
Underwriters shall reasonably object (other than a document that the Company believes in good faith, based on advice of counsel,
it is required by law to file).
(c) Delivery
of Registration Statements. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters,
without charge, conformed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits
filed therewith) and conformed copies of all consents and certificates of experts, and will also deliver to the Representatives,
without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits)
for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to XXXXX, except to the extent
permitted by Regulation S-T.
(d) Delivery
of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus
as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the
1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities
is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies
of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or
supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with
the Commission pursuant to XXXXX, except to the extent permitted by Regulation S-T.
(e) Blue
Sky Qualifications. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities
for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the
Representatives may reasonably designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Securities;
provided, however, that the
Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a
dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business
in any jurisdiction in which it is not otherwise so subject.
(f) Rule
158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the
benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.
(g) Use
of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified in
the Registration Statement, the General Disclosure Package and the Prospectus under “Use of Proceeds.”
(h) Listing. The Company will use its best efforts to effect and maintain the listing of the Common Stock (including the Securities) on the
NASDAQ Global Select Market (“NASDAQ”).
(i) Restriction
on Sale of Securities. During a period of 180 days from the date of the Prospectus, the Company will not, without the prior
written consent of the Representatives, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose
of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration
statement under the 1933 Act with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction
that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether
any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities,
in cash or otherwise. The foregoing sentence shall not apply to (A) the Securities to be sold hereunder, (B) any shares of Common
Stock issued by the Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof
and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C) any shares of Common Stock
issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the
Registration Statement, the General Disclosure Package and the Prospectus, (D) any shares of Common Stock issued pursuant to any
non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure
Package and the Prospectus, or (E) the filing of any registration statement on Form S−8 with respect to the foregoing clauses
(B), (C) and (D).
(j) If
the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a lock-up agreement described
in Section 5(k) hereof for an officer or director of the Company and provide the Company with notice of the impending release or
waiver at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending
release or waiver by a press release substantially in the form of Exhibit D hereto through a major news service at least two business
days before the effective date of the release or waiver.
(k) Reporting
Requirements. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission
pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall
report the use of proceeds from the issuance of the Shares as may be required under Rule 463 under the 1933 Act.
(l) Issuer
Free Writing Prospectuses. Each of the Company and the Selling Stockholder, severally and not jointly, agrees that, unless
it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities that would constitute
an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof,
required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives
will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule C-2 hereto and any “road show
that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. Each
of the Company and the Selling Stockholder, severally and not jointly, represents that it has treated or agrees that it will treat
each such free writing prospectus consented to, or deemed consented to, by the Representatives as an “issuer free writing
prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433
with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time
following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such
Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary
prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent
time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense,
such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. Each Underwriter represents
that it has not made, and agrees that, without the prior consent of the Company, it will not make any offer relating to the Securities
that would constitute a “free writing prospectus” required to be filed by the Company with the Commission or retained
by the Company under Rule 433; provided that the Company will be deemed to have consented to the Issuer Free Writing Prospectuses
listed on Schedule C-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i)
that has been reviewed by the Company.
(m) Testing-the-Waters
Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs
an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue
statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives
and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct
such untrue statement or omission.
(n) Emerging Growth Company Status. The Company will promptly notify the Representatives if the Company ceases to be an Emerging
Growth Company at any time prior to the later of (i) completion of the distribution of the Securities within the meaning of the
Securities Act and (ii) completion of the 180-day restricted period referred to in Section 3(i).
SECTION 4. Payment
of Expenses.
(a) Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its obligations and the obligations of the
Selling Stockholder under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including
financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery
to the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments
or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors,
(iii) the preparation, issuance and delivery of the certificates for the Securities to the Underwriters, including any stock or
other transfer
taxes and any stamp or other
duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and disbursements
of the Company’s counsel, accountants and other advisors, (v) the qualification of the Securities under securities laws
in accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable fees and disbursements
of counsel for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey and any supplement
thereto, (vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii) the costs and expenses of the
Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities,
including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any
consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers
of the Company and any such consultants, and the 50% of the cost of aircraft and other transportation chartered in connection with
the road show (it being understood that the other 50% of such private aircraft and other private transportation shall be the responsibility
of the Underwriters, except that the lodging, commercial airfare and individual expenses of the Underwriters shall be the responsibility
of the Underwriters), (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters
in connection with, the review by FINRA of the terms of the sale of the Securities (provided that the Company shall not be required
to reimburse or pay more than $25,000 of the reasonable fees of such counsel),(ix) the fees and expenses incurred in connection
with the listing of the Securities on the NASDAQ Global Select Market and (x) the costs and expenses (including, without limitation,
any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts
for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of
Section 1(a)(ii).
(b) Expenses
of the Selling Stockholder. The Selling Stockholder will pay all expenses incident to the
performance of its respective obligations under, and the consummation of the transactions contemplated by, this Agreement,
including (i) any stamp and other duties and stock and other transfer taxes, if any, payable upon the sale of the Securities
to the Underwriters and their transfer between the Underwriters pursuant to an agreement between such Underwriters, and (ii)
the fees and disbursements of the Selling Stockholder’s counsel and other advisors.
(c) Termination
of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5, Section 9(a)(i)
or (iii), Section 10 or Section 11 hereof, the Company shall reimburse the Underwriters for all of their out-of-pocket expenses,
including the reasonable fees and disbursements of counsel for the Underwriters.
(d) Allocation
of Expenses. The provisions of this Section shall not affect any agreement that the Company and the Selling Stockholder may
make for the sharing of such costs and expenses.
SECTION 5. Conditions
of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the
representations and warranties of the Company and the Selling Stockholder contained herein or in certificates of any officer of
the Company or any of its subsidiaries or on behalf of the Selling Stockholder delivered pursuant to the provisions hereof, to
the performance by the Company and the Selling Stockholder of their respective covenants and other obligations hereunder, and to
the following further conditions:
(a) Effectiveness
of Registration Statement; Rule 430A Information. The Registration Statement, including any Rule 462(b) Registration Statement,
has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or,
to the Company’s knowledge, contemplated; and the Company has
complied with each request
(if any) from the Commission for additional information. A prospectus containing the Rule 430A Information shall have been filed
with the Commission in the manner and within the time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective
amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the
requirements of Rule 430A.
(b) Opinion
of Counsel for Company. At the Closing Time, the Representatives shall have received the favorable opinion, dated the Closing
Time, of Xxxxxxxx & Xxxxx LLP, counsel for the Company, in form and substance satisfactory to counsel for the Underwriters,
together with signed or reproduced copies of such letter for each of the other Underwriters to the effect set forth in Exhibit
A hereto.
(c) Opinion
of Counsel for the Selling Stockholder. At the Closing Time, the Representatives shall have received the favorable opinion,
dated the Closing Time, of Mourant Ozannes, counsel for the Selling Stockholder, and Xxxxxxxx & Xxxxx LLP, special U.S. counsel
for the Selling Stockholder, in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced
copies of such letter for each of the other Underwriters to the effect set forth in Exhibit B hereto.
(d) Opinion
of Counsel for Underwriters. At the Closing Time, the Representatives shall have received the favorable opinion, dated the
Closing Time, of Xxxxxxxx & Xxxxxxxx LLP, counsel for the Underwriters, together with signed or reproduced copies of such letter
for each of the other Underwriters with respect to the matters set forth in Exhibit A, clauses (v), (vi) (solely as to preemptive
or other similar rights arising by operation of law or under the charter or by-laws of the Company), (viii), (x), (xiv) (solely
as to the information in the Prospectus under “Description of Capital Stock—Common Stock”), the penultimate paragraph
of Exhibit A hereto, and other related matters as the Representatives may require. In giving such opinion such counsel may rely,
as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law
of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the
Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent
they deem proper, upon certificates of officers and other representatives of the Company and its subsidiaries and certificates
of public officials.
(e) Officers’
Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which
information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change
in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received
a certificate of the Chief Executive Officer or the President of the Company and of the chief financial or chief accounting officer
of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations
and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at
and as of the Closing Time, and (iii) the Company has complied with all agreements and satisfied all conditions on its part
to be performed or satisfied at or prior to the Closing Time.
(f) Certificate
of Selling Stockholder. At the Closing Time, the Representatives shall have received a certificate of an Attorney-in-Fact on
behalf of the Selling Stockholder, dated the Closing Time, to the effect that (i) the representations and warranties of the Selling
Stockholder in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing
Time and (ii) the Selling Stockholder has complied with all agreements and all conditions on its part to be performed under this
Agreement at or prior to the Closing Time.
(g) Accountant’s
Comfort Letter. At the time of the execution of this Agreement, the Representative shall have received from PricewaterhouseCoopers
LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies
of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants’
“comfort letters” to underwriters with respect to the financial statements and certain financial information contained
in the Registration Statement, the General Disclosure Package and the Prospectus.
(h) Bring-down
Comfort Letter. At the Closing Time, the Representatives shall have received from PricewaterhouseCoopers LLP a letter, dated
as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (g)
of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing
Time.
(i) Approval
of Listing. At the Closing Time, the Securities shall have been approved for listing on the NASDAQ Global Select Market, subject
only to official notice of issuance.
(j) No
Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the
underwriting terms and arrangements relating to the offering of the Securities.
(k) Lock-up
Agreements. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of
Exhibit C hereto signed by the persons listed on Schedule D hereto.
(l) Maintenance
of Rating. Since the execution of this Agreement, there shall not have been any decrease in or withdrawal of the rating of
any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization”
(as defined for purposes of Rule 436(g) under the 0000 Xxx) or any notice given of any intended or potential decrease in or withdrawal
of any such rating or of a possible change in any such rating that does not indicate the direction of the possible change other
than a withdrawal or notice of withdrawal of the rating of the 9.25% senior notes due July 1, 2018 resulting from the Company providing
a notice of redemption with respect to such notes.
(m) Conditions
to Purchase of Option Securities. In the event that the Underwriters exercise their option provided in Section 2(b) hereof
to purchase all or any portion of the Option Securities, the representations and warranties of the Company and the Selling Stockholder
contained herein and the statements in any certificates furnished by the Company, any of its subsidiaries and the Selling Stockholder
hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall
have received:
(i) Officers’
Certificate. A certificate, dated such Date of Delivery, of the President or a Vice President of the Company and of the chief
financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to
Section 5(e) hereof remains true and correct as of such Date of Delivery.
(ii) Certificate
of Selling Stockholder. A certificate, dated such Date of Delivery, of an Attorney-in-Fact on behalf of the Selling Stockholder
confirming that the certificate delivered at the Closing Time pursuant to Section 5(f) remains true and correct as of such Date
of Delivery.
(iii) Opinion
of Counsel for Company. If requested by the Representative, the favorable opinion of Xxxxxxxx & Xxxxx LLP, counsel for
the Company, in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option
Securities to be
purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(b) hereof.
(iv) Opinion
of Counsel for the Selling Stockholder. If requested by the Representatives, the favorable opinion of Mourant Ozannes, counsel
for the Selling Stockholder, and Xxxxxxxx & Xxxxx LLP, special U.S. counsel for the Selling Stockholder, in form and substance
satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on
such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(c) hereof.
(v) Opinion
of Counsel for Underwriters. If requested by the Representatives, the favorable opinion of Xxxxxxxx & Xxxxxxxx LLP, counsel
for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and
otherwise to the same effect as the opinion required by Section 5(d) hereof.
(vi) Bring-down
Comfort Letter. If requested by the Representatives, a letter from PricewaterhouseCoopers LLP, in form
and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance
as the letter furnished to the Representatives pursuant to Section 5(g) hereof, except that the “specified date” in
the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.
(n) Additional
Documents. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have been furnished
with such documents and opinions as they may require for the purpose of enabling them to pass upon the issuance and sale of the
Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment
of any of the conditions, herein contained; and all proceedings taken by the Company and the Selling Stockholder in connection
with the issuance and sale of the Securities as herein contemplated shall be satisfactory in form and substance to the Representatives
and counsel for the Underwriters.
(o) Termination
of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled,
this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the
Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the
Representatives by notice to the Company and the Selling Stockholder at any time at or prior to Closing Time or such Date of Delivery,
as the case may be, and such termination shall be without liability of any party to any other party except as provided in Section
4 and except that Sections 1, 6, 7, 8, 15, 16 and 17 shall survive any such termination and remain in full force and effect.
SECTION 6. Indemnification.
(a) Indemnification
of Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined
in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its selling agents and each person, if any, who controls
any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:
(i) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A
Information, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading or arising out of any untrue
statement or alleged
untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written
Testing-the-Waters Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or
(B) in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing
of the offering of the Stock (“Marketing Materials”), including any roadshow or investor presentations made to investors
by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, Issuer
Free Writing Prospectus, any Written Testing-the-Waters Communication, Prospectus or in any Marketing Materials of a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
(ii) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject
to Section 6(e) below) any such settlement is effected with the written consent of the Company and the Selling Stockholder;
(iii) against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representatives), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this
indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement
or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including the
Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon
and in conformity with the Underwriter Information.
(b) Indemnification
of Underwriters by Selling Stockholder. The Selling Stockholder agrees to indemnify and hold harmless each Underwriter, its
Affiliates and selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933
Act or Section 20 of the 1934 Act to the extent and in the manner set forth in clauses (a)(i), (ii) and (iii) above;
provided that the Selling Stockholder shall be liable only to the extent that such untrue statement or alleged untrue statement
or omission or alleged omission has been made in the Registration Statement, any preliminary prospectus, the General Disclosure
Package, the Prospectus (or any amendment or supplement thereto) or any Issuer Free Writing Prospectus in reliance upon and in
conformity with the Selling Stockholder Information; provided, further, that the liability under this subsection of the Selling
Stockholder shall be limited to an amount equal to the aggregate gross proceeds after underwriting commissions and discounts, but
before expenses, to the Selling Stockholder from the sale of Securities sold by the Selling Stockholder hereunder.
(c) Indemnification
of Company, Directors and Officers and Selling Stockholder. Each Underwriter severally agrees to indemnify and hold harmless
the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, and the Selling Stockholder and each person,
if any, who controls the Selling Stockholder within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act against
any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section,
as incurred, but only with
respect to untrue statements
or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including
the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance
upon and in conformity with the Underwriter Information.
(d) Actions
against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced (through
the forfeiture of substantive rights or defenses) as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section
6(a) and 6(b) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified
pursuant to Section 6(c) above, counsel to the indemnified parties shall be selected by the Company and the Selling Stockholder.
An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to
the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In
no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel)
separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related
actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without
the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect
to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim
whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether
or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes
an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding
or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf
of any indemnified party.
(e) Settlement
without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered
into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have
received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying
party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.
(f) Other
Agreements with Respect to Indemnification. The provisions of this Section shall not affect any agreement among the Company
and the Selling Stockholder with respect to indemnification.
SECTION 7. Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless
an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified
party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling
Stockholder, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement
or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the
relative benefits referred
to in clause (i) above but also the relative fault of the Company and the Selling Stockholder, and on the one hand, and of the
Underwriters, on the other hand, in connection with the statements or omissions, which resulted in such losses, liabilities, claims,
damages or expenses, as well as any other relevant equitable considerations.
The relative benefits received
by the Company and the Selling Stockholder, on the one hand, and the Underwriters, on the other hand, in connection with the offering
of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds
from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company and the Selling
Stockholder, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case
as set forth on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth
on the cover of the Prospectus.
The relative fault of the
Company and the Selling Stockholder, on the one hand, and the Underwriters, on the other hand, shall be determined by reference
to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission
to state a material fact relates to information supplied by the Company or the Selling Stockholder or by the Underwriters and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Company and the Selling
Stockholder and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method
of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount
of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall
be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending
against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any
claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions
of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting commissions received
by such Underwriter in connection with the Shares underwritten by it and distributed to the public.
No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 0000 Xxx) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.
For purposes of this Section
7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934
Act and each Underwriter’s Affiliates and selling agents shall have the same rights to contribution as such Underwriter,
and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who
controls the Company or the Selling Stockholder within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act
shall have the same rights to contribution as the Company or the Selling Stockholder, as the case may be. The Underwriters’
respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Initial Securities set
forth opposite their respective names in Schedule A hereto and not joint.
The provisions of this
Section shall not affect any agreement among the Company and the Selling Stockholder with respect to contribution.
SECTION 8. Representations,
Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company or any of its subsidiaries or the Selling Stockholder submitted pursuant hereto, shall remain operative
and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling
agents, any person controlling any Underwriter, its officers or directors, any person controlling the Company or any person controlling
the Selling Stockholder and (ii) delivery of and payment for the Securities.
SECTION 9. Termination
of Agreement.
(a) Termination. The Representatives may terminate this Agreement, by notice to the Company and the Selling Stockholder, at any time at or prior
to the Closing Time (i) if there has been, in the judgment of the Representatives, since the time of execution of this Agreement
or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or
the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business,
or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving
a prospective change in national or international political, financial or economic conditions, in each case the effect of which
is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the completion of the
offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has
been suspended or materially limited by the Commission or the NASDAQ, or (iv) if trading generally on the NYSE Amex or the New
York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading
have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA
or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking
moratorium has been declared by either Federal or New York authorities.
(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other
party except as provided in Section 4 hereof, and provided further that Sections 1, 6, 7, 8, 15, 16 and 17 shall survive such termination
and remain in full force and effect.
SECTION 10. Default
by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery
to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”),
the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting
Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as
may be agreed upon and upon the terms herein set forth; if, however, the Representative shall not have completed such arrangements
within such 24-hour period, then:
(i) if
the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting
Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective
underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or
(ii) if
the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with
respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company
to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part
of any non-defaulting Underwriter.
No action taken pursuant
to this Section shall relieve any defaulting Underwriter from liability in respect of its default.
In the event of any such
default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing
Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant
Option Securities, as the case may be, either the (i) Representatives or (ii) the Company and the Selling Stockholder shall have
the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days
in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any
other documents or arrangements. As used herein, the term “Underwriter” includes any person substituted for an Underwriter
under this Section 10.
SECTION 11. Default
by the Selling Stockholder or the Company. (a) If the Selling Stockholder shall fail at the Closing Time or a Date of Delivery,
as the case may be, to sell and deliver the number of Securities which the Selling Stockholder is obligated to sell hereunder,
then the Underwriters may, at option of the Representatives, by notice from the Representatives to the Company, either (i) terminate
this Agreement without any liability on the fault of any non-defaulting party except that the provisions of Sections 1, 4, 6, 7,
8, 15, 16 and 17 shall remain in full force and effect or (ii) elect to purchase the Securities which the Company have agreed to
sell hereunder. No action taken pursuant to this Section 11 shall relieve the Selling Stockholder so defaulting from liability,
if any, in respect of such default.
In the event of a default
by the Selling Stockholder as referred to in this Section 11, each of the Representatives and the Company shall have the right
to postpone the Closing Time or any Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect
any required change in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents or
arrangements.
(b) If the Company shall
fail at the Closing Time or a Date of Delivery, as the case may be, to sell the number of Securities that it is obligated to sell
hereunder, then this Agreement shall terminate without any liability on the part of any nondefaulting party; provided, however,
that the provisions of Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall remain in full force and effect. No action taken pursuant to
this Section shall relieve the Company from liability, if any, in respect of such default.
SECTION 12. Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
by any standard form of telecommunication. Notices to the Underwriters shall be directed to Xxxxxxx Xxxxx at Xxx Xxxxxx Xxxx, Xxx
Xxxx, Xxx Xxxx 00000, attention of Syndicate Department (facsimile: (000) 000-0000), with a copy to ECM Legal (facsimile: (000)
000-0000) and Xxxxxx Xxxxxxx at 0000 Xxxxxxxx, Xxx Xxxx, Xxx Xxxx 00000, attention of Equity Syndicate Desk, with a copy to the
Legal Department; notices to the Company shall be directed to it at Xxxxxxxxxx Xxxxxx Xxxx, 0xx Xxxxx, 300 Xxxxx X. Xxxx Xxxxxxxxx,
Xxxxx 00, Xxxxxxx, Xxx Xxxxxx 00000, attention of Xxxxxx X. Dagger, Esq. with a copy to Xxxxxx X. Xxxxx, Xxxxxxxx & Xxxxx LLP,
000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, XX 00000; and notices to the Selling Stockholder shall be directed to c/o 3i Private Equity, 000
Xxxxxxx Xxxxxx, 0xx Xxxxx, Xxx Xxxx, XX
10017, attention of Xxx Xxxxx
with a copy to Xxxxxxxxx Xxxxxx, Xxxxxxxx & Xxxxx LLP, 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, XX 00000.
SECTION 13. No
Advisory or Fiduciary Relationship. Each of the Company and the Selling Stockholder acknowledges and agrees that (a) the purchase
and sale of the Securities pursuant to this Agreement, including the determination of the initial public offering price of the
Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company and the
Selling Stockholder, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering of the
Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent
or fiduciary of the Company, any of its subsidiaries or the Selling Stockholder, or its respective stockholders, creditors, employees
or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company
or the Selling Stockholder with respect to the offering of the Securities or the process leading thereto (irrespective of whether
such Underwriter has advised or is currently advising the Company, any of its subsidiaries or the Selling Stockholder on other
matters) and no Underwriter has any obligation to the Company or the Selling Stockholder with respect to the offering of the Securities
except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of each of the Company and the Selling Stockholder,
and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the
Securities and the Company and the Selling Stockholder has consulted its own respective legal, accounting, regulatory and tax advisors
to the extent it deemed appropriate.
SECTION 14. Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters, the Company and the Selling Stockholder
and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any
person, firm or corporation, other than the Underwriters, the Company and the Selling Stockholder and their respective successors
and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives,
any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement
and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters, the Company
and the Selling Stockholder and their respective successors, and said controlling persons and officers and directors and their
heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any
Underwriter shall be deemed to be a successor by reason merely of such purchase.
SECTION 15. Trial
by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates),
the Selling Stockholder and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.
SECTION 16. GOVERNING
LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.
SECTION 17. Consent
to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the
transactions contemplated hereby (“Related Proceedings”) shall be instituted in (i) the federal courts of the
United States of America located
in the City and County of
New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough
of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction
(except for proceedings instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”),
as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process,
summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any
suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to
the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and
agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been
brought in an inconvenient forum. Each party not located in the United States irrevocably appoints CT Corporation System as its
agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted
in any state or federal court in the City and County of New York. With respect to any Related Proceeding, each party irrevocably
waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from
jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled
in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts
or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect
of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign
Sovereign Immunities Act of 1976, as amended.
SECTION 18. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK
CITY TIME.
SECTION 19. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts
shall together constitute one and the same Agreement.
SECTION 20. Effect
of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
If the foregoing is in
accordance with your understanding of our agreement, please sign and return to the Company and the Selling Stockholder a counterpart
hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters, the Company
and the Selling Stockholder in accordance with its terms.
|
|
Very truly yours, |
|
|
|
|
|
|
|
PHIBRO ANIMAL HEALTH COMPANY |
|
|
|
|
|
|
|
By |
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
MAYFLOWER LIMITED PARTNERSHIP |
|
|
|
|
|
|
|
By |
|
|
|
|
|
Title: |
|
|
|
|
|
CONFIRMED AND ACCEPTED, |
|
as of the date first above written: |
|
|
|
XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX |
|
INCORPORATED |
|
XXXXXX XXXXXXX & CO. LLC |
|
|
|
By: XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX |
|
INCORPORATED |
|
|
|
By |
|
|
|
|
Authorized Signatory |
|
|
|
|
|
By: XXXXXX XXXXXXX & CO. LLC |
|
|
|
|
|
By |
|
|
|
|
Authorized Signatory |
|
|
For themselves and as Representatives of the other Underwriters
named in Schedule A hereto.
SCHEDULE A
The initial public offering price per share for the Securities shall
be $[l].
The purchase price per share for the Securities to be paid by the
several Underwriters shall be $[l], being an amount equal to the initial public offering
price set forth above less $[l] per share, subject to adjustment in accordance with
Section 2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the
Option Securities.
Name of Underwriter | |
Number of Initial Securities | |
| |
| | |
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx | |
| | |
Incorporated | |
| | |
Xxxxxx Xxxxxxx & Co. LLC | |
| | |
Barclays Capital Inc. | |
| | |
| |
| | |
| |
| | |
Total | |
| [l] | |
SCHEDULE B
| |
Number of Initial
Securities to be Sold | | |
Maximum Number of Option
Securities to Be Sold | |
PHIBRO ANIMAL HEALTH CORPORATION | |
| | | |
| | |
| |
| | | |
| | |
MAYFLOWER LIMITED PARTNERSHIP | |
| | | |
| | |
| |
| | | |
| | |
Total | |
| | | |
| | |
SCHEDULE C-1
Pricing Terms
1. The
Company and the Selling Stockholder are selling [l] shares of Common Stock.
2. The Selling Stockholder has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional [l]
shares of Common Stock.
3. The
initial public offering price per share for the Securities shall be $[l].
SCHEDULE C-2
Free Writing Prospectuses
[SPECIFY EACH ISSUER GENERAL USE FREE WRITING PROSPECTUS]
SCHEDULE D
List of Persons and Entities Subject to Lock-up
SCHEDULE E
Written Testing-the-Waters Communications
Exhibit A
FORM OF OPINION OF COMPANY’S COUNSEL
TO BE DELIVERED PURSUANT TO SECTION 5(b)
Exhibit B
FORM OF OPINION OF COUNSEL FOR THE SELLING STOCKHOLDERS
TO BE DELIVERED PURSUANT TO SECTION 5(c)
[Form of lock-up from directors, officers or other stockholders
pursuant to Section 5(k)]
Exhibit C
l,
2013
Xxxxxxx Lynch, Pierce, Xxxxxx &
Xxxxx
Incorporated,
Xxxxxx Xxxxxxx & Co. LLC
as Representative of the several
Underwriters to be named in the
within-mentioned Underwriting Agreement
c/o Merrill Lynch, Pierce, Xxxxxx
& Xxxxx
Incorporated
Xxx Xxxxxx Xxxx
Xxx Xxxx, Xxx Xxxx 00000
Re: Proposed Public
Offering by Phibro Animal Health Corporation
Dear Sirs:
The undersigned, a stockholder
[and an officer and/or director] of Phibro Animal Health Corporation, a New York corporation (the “Company”), understands
that Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated (“Xxxxxxx Xxxxx”) and Xxxxxx Xxxxxxx & Co. LLC (“Xxxxxx
Xxxxxxx”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company and
the Selling Stockholder providing for the public offering of shares (the “Securities”) of the Company’s common
stock, par value $0.0001 per share (the “Common Stock”). In recognition of the benefit that such an offering will confer
upon the undersigned as a stockholder [and an officer and/or director] of the Company, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting
Agreement that, during the period beginning on the date hereof and ending on the date that is 180 days from the date of the Underwriting
Agreement (subject to extensions as discussed below) (the “Restricted Period”), the undersigned will not, without the
prior written consent of Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of,
or otherwise dispose of or transfer any shares of the Company’s Common Stock or any securities convertible into or exchangeable
or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned
has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right
with respect to the registration of any of the Lock-up Securities, or file or cause to be filed any registration statement in connection
therewith, under the Securities Act of 1933, as amended, or (ii) enter into any swap or any other agreement or any transaction
that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether
any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise.
If the undersigned is an officer or director
of the Company, (1) Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx agree that, at least three business days before the effective date of any
release or waiver of the foregoing restrictions in connection with a transfer of shares of the Common Stock, Xxxxxxx Xxxxx and
Xxxxxx Xxxxxxx will notify the Company of the impending release or waiver, and (2) the Company has
agreed in the Underwriting Agreement to announce the impending release
or waiver by press release through a major news service at least two business days before the effective date of the release or
waiver. Any release or waiver granted by Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx hereunder to any such officer or director shall only
be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply
if (i) the release or waiver is effected solely to permit a transfer not for consideration and (ii) the transferee has agreed in
writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect
at the time of the transfer.
Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent of Xxxxxxx
Xxxxx and Xxxxxx Xxxxxxx, provided that (1) Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx receive a signed lock-up agreement for the balance
of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not
involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission
on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and (4) the undersigned does not otherwise
voluntarily effect any public filing or report regarding such transfers:
| (i) | as a bona fide gift or gifts or charitable contribution; or |
| (ii) | by will or intestacy; or |
| (iii) | to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship
by blood, marriage or adoption, not more remote than first cousin); or |
| (iv) | as a distribution to limited partners, stockholders or other similar parties of the
undersigned; or |
| (v) | to the undersigned’s affiliates or to any investment fund or other entity controlled
or managed by the undersigned. |
Furthermore, the undersigned
may (1) sell shares of Common Stock of the Company purchased by the undersigned on the open market following the Public Offering
if and only if (i) such sales are not required to be reported in any public report or filing with the Securities Exchange Commission,
or otherwise and (ii) the undersigned does not otherwise voluntarily effect any public filing or report regarding such sales; (2)
establish a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided that
(i) such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii) no public report or filing
is required or voluntarily made in connection therewith; (3) exercise an option to purchase shares of Common Stock granted under
any stock incentive plan or stock purchase plan of the Company, including on a “net” basis, provided that (i) the underlying
shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter, (ii) in the event
of an exercise on a “net” basis, the Company becomes the owner of the shares of Common Stock surrendered in the net
exercise, and (iii) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance
with Section 16 of the Securities Exchange Act of 1934, as amended; (4) [exercise by BFI Co., LLC on a “net” basis
of the Common Stock Purchase Warrant expiring August 1, 2014 between July 1, 2014 and August 1, 2014, provided that (i) the underlying
shares of Common Stock received upon such exercise shall remain subject to this lock-up agreement, (ii) in the event of an exercise
on a “net” basis, the Company becomes the owner of the shares of Common Stock surrendered in the net exercise and (iii)
any related filing required under Section 16 of the Securities Exchange Act of 1934, as amended, shall disclose in a footnote that
such filing is in respect of the net exercise of a warrant expiring August 1, 2014.] [and] (5)
the transfer, sale, tender or other disposition
of Common Stock to a bona fide third party pursuant to a tender offer for securities of the Company or any merger, consolidation
or other business combination involving a Change of Control of the Company occurring after the settlement of the Offering, that,
in each case, has been approved by the board of directors of the Company (including, without limitation, entering into any lock-up,
voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common
Stock in connection with any such transaction, or vote any Common Stock in favor of any such transaction); provided that all shares
of Common Stock subject to this lock-up agreement that are not so transferred, sold, tendered or otherwise disposed of remain subject
to this lock-up agreement; and provided, further, that it shall be a condition of transfer, sale, tender or other disposition that
if such tender offer or other transaction is not completed, any Common Stock subject to this lock-up agreement shall remain subject
to the restrictions herein. For the purposes of this paragraph, “Change of Control” means the consummation of any bona
fide third party tender offer, merger, consolidation or other similar transaction, the result of which is that any “person”
(as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than the Company or its subsidiaries, becomes
the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of 100% of the total voting power of the voting
stock of the Company.
This lock-up agreement
shall automatically terminate, and the undersigned shall be released from its obligations hereunder, upon the earliest to occur,
if any, of (i) either Representative, on the one hand, or the Company, on the other hand, have advised the other(s) in writing
prior to the closing of the Offering, that it has determined not to proceed with the Offering, (ii) the Company files an application
to withdraw the registration statement related to the Offering, (iii) the Underwriting Agreement is executed but is terminated
prior to the closing¶ of the Offering (other than the provisions thereof which survive termination) prior to payment for and
delivery of the shares of Common Stock to be sold thereunder, or (iv) August 15, 2014, in the event that the Underwriting Agreement
has not been executed by such date.
The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer
of the Lock-Up Securities except in compliance with the foregoing restrictions.
|
Very truly yours, |
|
|
|
|
|
Signature: |
|
|
|
|
|
|
Print Name: |
|
Exhibit D
Form
of Press Release
TO
BE ISSUED PURSUANT TO SECTION 3(j)
PHIBRO ANIMAL HEALTH CORPORATION
[l], 2014
PHIBRO ANIMAL HEALTH CORPORATION (the “Company”) announced
today that BofA Xxxxxxx Xxxxx and Xxxxxx Xxxxxxx, the book-running managers in the Company’s recent public sale of [l]
shares of common stock, is [waiving] [releasing] a lock-up restriction with respect to [l]
shares of the Company’s common stock held by [certain officers or directors] [an officer or director] of the Company. The
[waiver] [release] will take effect on , 2014, and the shares may be sold on or after such date.
This press release is not an offer for sale of the securities
in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold
in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.